NCT07504484 — Ying Yuan, MD neoantigen vaccine trial
Safety and Efficacy of Neoantigen-Based Personalized Immunotherapy as Consolidation Therapy After Standard Adjuvant Treatment in Resectable Stage III Colorectal Cancer or Non-Small Cell Lung Cancer
Registry record
| Registry ID | NCT07504484 ↗ |
|---|---|
| Lead sponsor | Ying Yuan, MD |
| Collaborators | Hangzhou Neoantigen Therapeutics Co., Ltd. |
| Phase | Phase 1 |
| Status | Completed |
| Indication | CRC (Colorectal Cancer), Non Small Lung Cancer |
| Enrollment | 6 participants |
| Start date | 2020-10-30 |
| Primary completion | 2023-12-31 |
| Last registry update | 31 Mar 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07504484), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07504484?
NCT07504484 (Safety and Efficacy of Neoantigen-Based Personalized Immunotherapy as Consolidation Therapy After Standard Adjuvant Treatment in Resectable Stage III Colorectal Cancer or Non-Small Cell Lung Cancer) is registered on ClinicalTrials.gov as Phase 1, sponsored by Ying Yuan, MD.
Is NCT07504484 recruiting?
As of the 2026-03-31 registry update, NCT07504484 is listed as "Completed". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07504484?
The lead sponsor is Ying Yuan, MD. Collaborators: Hangzhou Neoantigen Therapeutics Co., Ltd..
What condition does NCT07504484 study?
The registered conditions are CRC (Colorectal Cancer), Non Small Lung Cancer. Primary completion is listed as 2023-12-31.
Are results available for NCT07504484?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07504484.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.